Cleothena Enterprises

Cleothena Enterprises is a privately held, clinical-stage biotechnology company based in Australia that focuses on developing novel therapeutics for underserved neurological conditions. The company's lead candidate, OXT-328, is a topical gel formulation of a new chemical entity currently in Phase 2 clinical development for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). Cleothena utilizes a high-efficiency, minimalist operational model, leveraging strategic partnerships for regulatory execution, medical writing, and intellectual property management. The company aims to accelerate the translation of scientific discovery into clinical validation through a tech-informed approach and streamlined development pathways.